Category Patents VS Innovation

FDA has low efficacy threshold for approving cancer medicines

Evergreening is common

The purported ‘innovation dip’ is an artefact of the time periods previously studied. Reports of declining innovation need to be considered in the context of their timescale and perspective.

A liberal economists perspective on why patents may not promote innovation.

IP on basic research reduces subsequent scientific research and product development

Voluntary licensing and tiered pricing are ineffective and help Gilead Sciences maintain market dominance – essay by Médecins du Monde

On Average 3.5 patents per drug in 2005! and How private-sector follow-on patents affect socially responsible licensing efforts.

Patent protection leads to decreased quality of diagnostics (in gene research)

Patent protection does not contribute to innovation (in gene research)

Economic proof of ‘strategic’ vs innovative patents

Loss of pharma revenue following lower prices will not jeopardise drug research

Nature editorial blasts university relationships with patent trolls

Patents slow innovation – case study of human gene patenting by Celera

University TTOS turning to patent trolls (PAEs)

Current (US) patent system promotes long-term instead of preventative treatments (Cancer)

TPP works against NTD R&D